Trial Profile

A Phase Ib, Open-Label Trial of MOv18 IgE in Patients With Advanced Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MOv18 IgE (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Epsilogen

Most Recent Events

19 Sep 2024 Status changed from not yet recruiting to recruiting.
09 Aug 2024 Status changed to not yet recruiting.
08 Jul 2024 According to an Epsilogen media release, the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA)and the phase Ib trial expected to begin in H2 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com